Clinical trials in traumatic brain injury: lessons for the future
Related Experiment Video
Updated: Aug 29, 2026
Murine Model of Controlled Cortical Impact for the Induction of Traumatic Brain Injury
Published on: August 16, 2019
Egon M R Doppenberg1, Sung C Choi, Ross Bullock
1Department of Neurosurgery, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA.
Abstract:
Thus far, none of the neuroprotective drugs that have been tested to reduce or prevent secondary ischemic brain damage have been shown clear benefit. We will attempt to identify factors that may be responsible for some of these failures. We also will give our thoughts on how to prevent these pitfalls in the usefulness and criteria for use of animal models for traumatic brain injury to depict human head injury are discussed. Clearly, mechanism-driven trials, in which individual pathophysiological mechanisms are targeted, are more likely to show benefit in this heterogeneous patient population. Other factors, such as the effect of brain penetration, safety and tolerability of the compound, and the interface between the pharmaceutical industry and academics are a major influence in the success of these trials. Furthermore, the way trials have been analyzes in the past may not always have been be the most appropriate to show benefits. It is clear that a multi-targeted approach is necessary to address the complicated and closely related mechanisms seen after traumatic and or ischemic brain damage.
Insights
Neuroprotective drug trials for brain injury have largely failed due to issues with animal models and trial design. A multi-targeted approach is needed for better outcomes in treating ischemic and traumatic brain damage.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Numerous neuroprotective drugs have failed to demonstrate efficacy in preventing secondary brain damage from ischemia.
- Existing animal models for traumatic brain injury (TBI) may not accurately depict human head injury, contributing to trial failures.
Purpose of the Study:
- To identify factors contributing to the failure of neuroprotective drug trials.
- To discuss improvements for animal models in TBI research.
- To propose strategies for more successful clinical trials targeting brain injury.
Main Methods:
- Review of past clinical trial methodologies and outcomes in neuroprotection.
- Analysis of limitations in current animal models for traumatic brain injury.
- Discussion of critical factors influencing trial success, including drug properties and industry-academic collaboration.
Main Results:
- Failures attributed to inadequate animal models, inappropriate trial analysis, and overlooking critical drug properties like brain penetration and safety.
- Heterogeneous patient populations in brain injury trials necessitate targeted approaches.
Conclusions:
- Mechanism-driven clinical trials targeting specific pathophysiological pathways are more promising.
- A multi-targeted therapeutic strategy is essential for addressing complex brain damage mechanisms.
- Improved animal models and trial designs are crucial for advancing neuroprotection research.
